These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 26848862)

  • 1. FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
    Chougule RA; Kazi JU; Rönnstrand L
    Oncotarget; 2016 Mar; 7(9):9964-74. PubMed ID: 26848862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
    Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
    Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia.
    Kazi JU; Rönnstrand L
    Mol Oncol; 2013 Jun; 7(3):402-18. PubMed ID: 23246379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
    Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
    Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABL2 suppresses FLT3-ITD-induced cell proliferation through negative regulation of AKT signaling.
    Kazi JU; Rupar K; Marhäll A; Moharram SA; Khanum F; Shah K; Gazi M; Nagaraj SR; Sun J; Chougule RA; Rönnstrand L
    Oncotarget; 2017 Feb; 8(7):12194-12202. PubMed ID: 28086240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
    Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
    Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BEX1 acts as a tumor suppressor in acute myeloid leukemia.
    Lindblad O; Li T; Su X; Sun J; Kabir NN; Levander F; Zhao H; Lu G; Rönnstrand L; Kazi JU
    Oncotarget; 2015 Aug; 6(25):21395-405. PubMed ID: 26046670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.
    Yoshimoto G; Miyamoto T; Jabbarzadeh-Tabrizi S; Iino T; Rocnik JL; Kikushige Y; Mori Y; Shima T; Iwasaki H; Takenaka K; Nagafuji K; Mizuno S; Niiro H; Gilliland GD; Akashi K
    Blood; 2009 Dec; 114(24):5034-43. PubMed ID: 19808698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
    Mizuki M; Fenski R; Halfter H; Matsumura I; Schmidt R; Müller C; Grüning W; Kratz-Albers K; Serve S; Steur C; Büchner T; Kienast J; Kanakura Y; Berdel WE; Serve H
    Blood; 2000 Dec; 96(12):3907-14. PubMed ID: 11090077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling.
    Moharram SA; Chougule RA; Su X; Li T; Sun J; Zhao H; Rönnstrand L; Kazi JU
    Oncotarget; 2016 Sep; 7(36):57770-57782. PubMed ID: 27458164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
    Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
    Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.
    Jacobi A; Thieme S; Lehmann R; Ugarte F; Malech HL; Koch S; Thiede C; Müller K; Bornhäuser M; Ryser M; Brenner S
    Exp Hematol; 2010 Mar; 38(3):180-90. PubMed ID: 20035824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.
    Leischner H; Albers C; Grundler R; Razumovskaya E; Spiekermann K; Bohlander S; Rönnstrand L; Götze K; Peschel C; Duyster J
    Blood; 2012 Apr; 119(17):4026-33. PubMed ID: 22411868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FLT3 mutations in acute myeloid leukemia cell lines.
    Quentmeier H; Reinhardt J; Zaborski M; Drexler HG
    Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.
    Brandts CH; Sargin B; Rode M; Biermann C; Lindtner B; Schwäble J; Buerger H; Müller-Tidow C; Choudhary C; McMahon M; Berdel WE; Serve H
    Cancer Res; 2005 Nov; 65(21):9643-50. PubMed ID: 16266983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Marhäll A; Heidel F; Fischer T; Rönnstrand L
    Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo.
    Nabinger SC; Li XJ; Ramdas B; He Y; Zhang X; Zeng L; Richine B; Bowling JD; Fukuda S; Goenka S; Liu Z; Feng GS; Yu M; Sandusky GE; Boswell HS; Zhang ZY; Kapur R; Chan RJ
    Leukemia; 2013 Feb; 27(2):398-408. PubMed ID: 23103841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLT3-ITD expression levels and their effect on STAT5 in AML with and without NPM mutations.
    Seedhouse CH; Pallis M; Grundy M; Shang S; Russell NH
    Br J Haematol; 2009 Dec; 147(5):653-61. PubMed ID: 19775300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Src family kinase LCK cooperates with oncogenic FLT3/ITD in cellular transformation.
    Marhäll A; Kazi JU; Rönnstrand L
    Sci Rep; 2017 Oct; 7(1):13734. PubMed ID: 29062038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.
    Gerloff D; Grundler R; Wurm AA; Bräuer-Hartmann D; Katzerke C; Hartmann JU; Madan V; Müller-Tidow C; Duyster J; Tenen DG; Niederwieser D; Behre G
    Leukemia; 2015 Mar; 29(3):535-47. PubMed ID: 25092144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.